Solventum (SOLV) announced the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Knight will oversee global commercial and R&D operations across Solventum’s MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Hanson said, “Heather’s appointment to the new role of Chief Commercial Officer reflects Solventum’s commitment to building a high-performing organization and progress to becoming a leading global MedTech company. By aligning our go-to-market strategy under one leader, we will enhance our ability to leverage the size and scale of Solventum, driving more coordinated execution and profitable growth. Heather is an industry veteran who brings a long history of strategic vision, commercial discipline and deep sector experience that will be instrumental as we execute our transformation as a standalone company.” In connection with Knight’s appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart Solventum, effective December 31, 2025. This change does not impact Solventum’s financial guidance.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOLV:
- Apple initiated, DraftKings downgraded: Wall Street’s top analyst calls
- Solventum initiated with a Neutral at UBS
- Solventum Corporation: Hold Rating Amid Balanced Valuation and Growth Challenges
- Strategic Business Sale and Optimistic Financial Targets Justify Buy Rating for Solventum Corporation
- Solventum price target raised to $82 from $79 at Wells Fargo